About this trial

The purpose of the clinical investigation is to evaluate the safety of the FLEXIGO delivery catheter for transvenous pacing lead implantation.

Eligibility criteria

Qualifiers

Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)

Patient planned for a de novo implantation of any Single Chamber (SR) or Dual Chamber (DR) CE marked pacemaker

Patient planned for a catheter-guided implantation in the interventricular septum area

Patient planned for the implantation of any CE marked ventricular pacing lead compatible with the FLEXIGO delivery catheter

Disqualifiers

Patient planned for a device upgrade, or a device or a lead replacement

Patient with a congenital heart disease

Patient with significant hypertrophic cardiomyopathy, cardiac amyloidosis or obstructive hypertrophic cardiomyopathy

Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%

Trial design

Treatments tested in this trial

  • Use of FLEXIGO delivery catheter

Treatment groups

216 Participants
are divided into 1 treatment group

Locations

3
Portugal
ULS de Coimbra Coimbra Portugal
Spain
Hospital Universitario Virgen de las Nieves Granada Spain
Hospital Universitari i Politècnic La Fe Valencia Spain

Sponsors and collaborators

MicroPort CRM

Lead sponsor